News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symbios Clinical, Inc., a Medical Device CRO and Subsidiary of Medpace, Inc., Changes Name to Medpace Medical Device Concluding Integration Activities


11/18/2010 9:36:57 AM

CINCINNATI, OH--(Marketwire - November 18, 2010) -

Medpace, Inc., a global, full-service clinical research organization (CRO), announced that it has completed integration activities with Symbios Clinical, a CRO dedicated to medical device clinical trials, which Medpace aquired earlier this year. Symbios Clinical will now be known as Medpace Medical Device (MMD) and will continue to provide expertise in pre-market, post-approval and post-market / outcomes trials.

MMD is a fully integrated subsidiary of Medpace, providing sponsors with the access to Medpace therapeutic and executive level expertise, integrated core lab and imaging services, enhanced safety management services and global infrastructure. This will further enhance MMD's leadership position as a best-in-class CRO for the design and execution of medical device trials.

The management team will remain in place, and the main offices for MMD will remain in Minneapolis with the added flexibility to consult and conduct device trials on a global basis as a member of the Medpace group of companies.

"Through this integration we believe we offer our customers something completely different and unique -- true medical device expertise with a comprehensive and global service offering through one provider," said Ryan Wilson, General Manager, Medpace Medical Device. "This allows us to have tighter control over project timelines and make the outsourcing experience more seamless for our customers."

MMD, formerly Symbios, was acquired by Medpace in March 2010. Over the last seven months the Medpace and the MMD teams have worked to integrate functions for both companies. The result will greatly expand MMD's service offering and enhance its capabilities for its customers, as well as strengthen Medpace capabilities overall.

ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With 900+ employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace.

Visit the Medpace website at: www.medpace.com

ABOUT MEDPACE MEDICAL DEVICE (MMD)

Medpace Medical Device (MMD) is a full service medical device CRO in the Minneapolis, Minnesota area. MMD offers trial design, site management, project management, monitoring, biostatistics, regulatory support, and data management for companies with medical devices in the human clinical trial phase. MMD has the ability to conduct medical device clinical trials for small or large sponsors, and for trials in both the US and worldwide.

Visit Medpace Medical Device at: www.medpace.com/device


Contact:
Mary Kuramoto
+1 513-579-9911 X 2523
m.kuramoto@medpace.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES